Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

As an RNAi-based therapeutic targeting ANGPTL3, investigational zodasiran has the potential to treat HoFH in a fundamentally different manner from traditional LDL-C–lowering therapies,” said James ...

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹ ...

OSAKA, Japan & CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Jun 30, 2025-- Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC ...

Microsoft is shaking up its Office and Copilot business teams as part of an AI reorg. LinkedIn chief Ryan Roslansky is Microsoft’s new Office chief.

LinkedIn CEO Ryan Roslansky will oversee Microsoft Office apps in a new role aimed at unifying the company’s AI strategy across platforms including Microsoft 365, Dynamics 365, and LinkedIn.

Salesforce recently announced a strategic partnership with Takeda, a global pharmaceutical company, as part of an expansion of its Life Sciences Cloud. This move signals Salesforce’s commitment to ...

Salesforce (CRM) announced that Takeda has selected Salesforce Life Sciences Cloud for Customer Engagement to strengthen its involvement with healthcare professionals seamlessly. The company will ...

Takeda teams will have access to real-time insights and intelligent analytics embedded directly in their workflows to drive more streamlined and personalized communication with healthcare ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

Julie Kim is due to be promoted to chief executive of Takeda Pharmaceutical Co. next year. First, though, the head of the Japanese drugmaker’s US operations had some business advice to share ...